147 related articles for article (PubMed ID: 36008233)
1. Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
Prudden HJ; Achilles SL; Schocken C; Broutet N; Canfell K; Akaba H; Basu P; Bhatla N; Chirenje ZM; Delany-Moretlwe S; Denny L; Gamage DG; Herrero R; Hutubessy R; Villa LL; Murillo R; Schiller JT; Stanley M; Temmerman M; Zhao F; Ogilvie G; Kaslow DC; Dull P; Gottlieb SL;
Vaccine; 2022 Sep; 40(41):5843-5855. PubMed ID: 36008233
[TBL] [Abstract][Full Text] [Related]
2. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
3. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
4. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and other milestones for human papillomavirus vaccine introduction.
Pagliusi SR; Teresa Aguado M
Vaccine; 2004 Dec; 23(5):569-78. PubMed ID: 15630792
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?
Amponsah-Dacosta E; Blose N; Nkwinika VV; Chepkurui V
Front Public Health; 2022; 10():799984. PubMed ID: 35174123
[TBL] [Abstract][Full Text] [Related]
7. Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.
Gottlieb SL; Ndowa F; Hook EW; Deal C; Bachmann L; Abu-Raddad L; Chen XS; Jerse A; Low N; MacLennan CA; Petousis-Harris H; Seib KL; Unemo M; Vincent L; Giersing BK;
Vaccine; 2020 Jun; 38(28):4362-4373. PubMed ID: 32359875
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Distribution of Vaccine-Preventable Genital Human Papillomavirus(HPV) Genotypes in Ghanaian Women Presenting for Screening.
Donkoh ET; Asmah RH; Agyemang-Yeboah F; Dabo EO; Wiredu EK
Cancer Control; 2022; 29():10732748221094721. PubMed ID: 35536890
[TBL] [Abstract][Full Text] [Related]
9. The European response to the WHO call to eliminate cervical cancer as a public health problem.
Arbyn M; Gultekin M; Morice P; Nieminen P; Cruickshank M; Poortmans P; Kelly D; Poljak M; Bergeron C; Ritchie D; Schmidt D; Kyrgiou M; Van den Bruel A; Bruni L; Basu P; Bray F; Weiderpass E
Int J Cancer; 2021 Jan; 148(2):277-284. PubMed ID: 32638362
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer prevention: Human papillomavirus testing as primary screening.
Desai S; Zhu MJ; Lapidos-Salaiz I
Cancer; 2022 Mar; 128(5):939-943. PubMed ID: 34767263
[TBL] [Abstract][Full Text] [Related]
11. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
[TBL] [Abstract][Full Text] [Related]
12. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
13. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study.
Mihretie GN; Liyeh TM; Ayele AD; Belay HG; Yimer TS; Miskr AD
Reprod Health; 2022 Jun; 19(1):136. PubMed ID: 35689288
[TBL] [Abstract][Full Text] [Related]
14. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators.
Spayne J; Hesketh T
BMJ Open; 2021 Sep; 11(9):e052016. PubMed ID: 34475188
[TBL] [Abstract][Full Text] [Related]
15. Integration of other services with human papillomavirus vaccination; lessons from earlier in the life course highlight the need for new policy and implementation evidence.
Morgan C; Giattas MR; Holroyd T; Pfitzer A; Engel D; Sidibe A; Holloway M; Bloem P; Fields R; Shimp L; Kumar S
Vaccine; 2022 Mar; 40 Suppl 1():A94-A99. PubMed ID: 35105493
[TBL] [Abstract][Full Text] [Related]
16. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management.
Brinkman JA; Caffrey AS; Muderspach LI; Roman LD; Kast WM
Eur J Gynaecol Oncol; 2005; 26(2):129-42. PubMed ID: 15857016
[TBL] [Abstract][Full Text] [Related]
17. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community.
Egbon M; Ojo T; Aliyu A; Bagudu ZS
BMC Public Health; 2022 Aug; 22(1):1611. PubMed ID: 36002832
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
19. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
20. Combining cervical cancer screening for mothers with schoolgirl vaccination during human papillomavirus (HPV) vaccine implementation in South Africa: results from the VACCS1 and VACCS2 trials.
Dreyer G; Botha MH; Snyman LC; Visser C; Burden R; Laubscher N; Grond B; Richter K; Becker PJ; Harvey J; van der Merwe FH
Int J Gynecol Cancer; 2022 May; 32(5):592-598. PubMed ID: 35078829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
